ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.72
0.56%
US Tech 100
17,658.00
0.32%
S&P 500
5,214.08
0.51%
US Dollar vs CAD
1.36854
0.05%
Bitcoin
62,837.36
-0.33%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. ImmunoPrecise Antibodies Ltd (IPA)

  7. ImmunoPrecise Antibodies Ltd (IPA) News

IPA

ImmunoPrecise Antibodies (IPA)

ImmunoPrecise Antibodies Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IPA
DateTimeSourceHeadlineSymbolCompany
03/28/20241:35PMBusiness WireInterSystems et BioStrand, filiale d’IPA, collaborent au lancement de l’intégration innovante de la recherche vectorielle et de LENSai dans les applications de soins de santé pilotées par l’IANASDAQ:IPAImmunoPrecise Antibodies Ltd
03/28/20246:02AMBusiness WireInterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare ApplicationsNASDAQ:IPAImmunoPrecise Antibodies Ltd
03/20/202412:52PMBusiness WireIPA acquiert l'instrument Carterra LSA® pour améliorer la découverte d'anticorps et renforcer ses développements en matière d'IANASDAQ:IPAImmunoPrecise Antibodies Ltd
03/20/20246:02AMBusiness WireIPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI DevelopmentsNASDAQ:IPAImmunoPrecise Antibodies Ltd
03/14/20246:39PMBusiness WireIPA présente ses résultats financiers et les récents points forts de son activité pour le troisième trimestre de l’exercice 2024*NASDAQ:IPAImmunoPrecise Antibodies Ltd
03/14/20247:05AMBusiness WireIPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*NASDAQ:IPAImmunoPrecise Antibodies Ltd
03/07/20242:24PMBusiness WireBioStrand, filiale d'IPA, annonce une avancée majeure dans les sciences du vivant avec son Advanced Foundation AI Model utilisant l'empilement LLM et la technologie HYFTNASDAQ:IPAImmunoPrecise Antibodies Ltd
03/07/202410:19AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
03/07/20246:02AMBusiness WireIPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT TechnologyNASDAQ:IPAImmunoPrecise Antibodies Ltd
03/04/20243:50PMBusiness WireL'IPA publiera ses résultats financiers et les faits marquants de sa récente activité pour le troisième trimestre de l'exercice 2024, le 14 mars 2024NASDAQ:IPAImmunoPrecise Antibodies Ltd
03/04/20247:01AMBusiness WireIPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024NASDAQ:IPAImmunoPrecise Antibodies Ltd
02/23/20244:29PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
02/23/20244:26PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IPAImmunoPrecise Antibodies Ltd
02/15/20242:12PMEdgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:IPAImmunoPrecise Antibodies Ltd
01/10/202412:53PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IPAImmunoPrecise Antibodies Ltd
01/10/202412:33PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:IPAImmunoPrecise Antibodies Ltd
12/14/20232:08PMBusiness WireIPA présente ses résultats financiers et les récents points forts de son activité pour le deuxième trimestre de l’exercice 2024*NASDAQ:IPAImmunoPrecise Antibodies Ltd
12/14/20237:48AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
12/14/20237:38AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
12/14/20237:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
12/14/20237:01AMBusiness WireIPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*NASDAQ:IPAImmunoPrecise Antibodies Ltd
12/08/20238:57PMBusiness WireIPA annonce la clôture d'une offre publique d'actions ordinaires pour un montant de 1 265 million de dollarsNASDAQ:IPAImmunoPrecise Antibodies Ltd
12/08/20234:11PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
12/08/20234:00PMBusiness WireIPA Announces Closing of $1.265 Million Public Offering of Common SharesNASDAQ:IPAImmunoPrecise Antibodies Ltd
12/07/20233:53PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IPAImmunoPrecise Antibodies Ltd
12/06/20234:19PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
12/06/20236:57AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
12/06/20236:00AMBusiness WireIPA annonce le prix des actions ordinaires de son émission publique de 1,1 million USDNASDAQ:IPAImmunoPrecise Antibodies Ltd
12/06/20236:00AMBusiness WireIPA Announces Pricing of $1.1 Million Public Offering of Common SharesNASDAQ:IPAImmunoPrecise Antibodies Ltd
12/06/20235:01AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
 Showing the most relevant articles for your search:NASDAQ:IPA

Your Recent History

USOTC
TXTM
ProText Mobility (PK)
USOTC
EMGE
Emergent Health (PK)
USOTC
SONG
Music Licensing (PK)
USOTC
SHMP
NaturalShrimp (QB)
USOTC
RDAR
Raadr (PK)
USOTC
ECSL
Ecare Solutions (PK)
USOTC
RONN
Ronn Motor (PK)
USOTC
BMXI
Brookmount Explorations (PK)
USOTC
YCRM
Yuenglings Ice Cream (PK)
USOTC
IPIX
Innovation Pharmaceuticals (CE)
USOTC
CLNV
Clean Vision (QB)
USOTC
ELTP
Elite Pharmaceuticals (QB)
USOTC
GSTC
Globestar Therapeutics (PK)
NASDAQ
AVXL
Anavex Life Sciences
NASDAQ
NVDA
NVIDIA
USOTC
ERHE
ERHC Energy (CE)
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved